---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-012303"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2025-04-17T23:59:59+00:00"
generated_at: "2026-05-23T11:59:01.384415+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# NRx Pharmaceuticals boosts ATM offering capacity to $20M; previously sold $1.8M

## Summary
- Maximum aggregate offering price increased to $20,000,000 under ATM agreement with H.C. Wainwright & Co.
- Approximately $1.8 million in common stock sold prior to the increase.
- Prospectus supplement filed on April 17, 2025 to register the additional shares.
- Legal opinion on share validity filed as Exhibit 5.1.

## SEC filing metadata
- accession: 0001437749-25-012303
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2025-04-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000143774925012303/0001437749-25-012303-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000143774925012303/nrxp20250417_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-012303
- JSON: https://secwatch.observer/filing/0001437749-25-012303.json
- Plain text: https://secwatch.observer/filing/0001437749-25-012303.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.